Amgen's PCSK9 Patent Win: A Long-Term Value Shift?
This article was originally published in Scrip
Executive Summary
Amgen Inc. may have won a battle in its lawsuit involving two patents on its proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor Repatha (evolocumab) against Sanofi SA and Regeneron Pharmaceuticals Inc., which market a competing drug, Praluent (alirocumab), but the California biotech giant is far from winning the war – that is, making the prophesied blockbuster profits on its medicine.
You may also be interested in...
1Q Earnings Preview: What To Expect From US, EU Big Hitters
The slow drip of pharma industry earnings announcements that began on April 19 with Roche and Johnson & Johnson will turn into a veritable stream over the next couple of weeks. Scrip takes a look at expectations around some of the main firms due to report.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.